Kodiak Sciences Q2 2026: $65.6M Net Loss, Going Concern Warning, Cash Runway into 2027
KOD has more than doubled off its 52-week low of $8.29.
Summary
Kodiak Sciences filed its Q2 2026 10-Q, reporting a $65.6 million net loss and $125.9 million in cash. The company reiterated a going concern warning, stating cash may not cover the next 12 months, and provided detailed clinical trial updates with key data readouts expected in September and December 2026.
Key Events · Earnings and Guidance · KOD
-
Q2 2026 Net Loss of $65.6M
The net loss widened to $65.6 million in Q2 2026 from $54.3 million a year earlier, bringing the first-half loss to $123.8 million.
-
Going Concern Warning Reiterated
Existing cash and equivalents of $125.9 million may not be sufficient to meet anticipated operating and capital expenditure requirements for the 12 months following the report date, raising substantial doubt about the company's ability to continue as a going concern.
-
Cash Runway into 2027
Management believes current cash will support operations into 2027, but not necessarily for the full 12 months. The company plans to raise additional capital through equity or debt financings, collaborations, or similar transactions.
-
Lease Termination and New Option
In July 2026, the company terminated its lease for 1200 Page Mill Road and received an option, exercisable through March 1, 2027, to lease a separate building at 1100 Page Mill Road with certain incentives.
Analysis · KOD · Life Sciences
A $65.6 million net loss for Q2 2026 underscores the financial strain at Kodiak Sciences, which held $125.9 million in cash and equivalents as of June 30, 2026. The company reiterated substantial doubt about its ability to continue as a going concern, stating that existing cash may not be sufficient to meet operating and capital expenditure requirements for the next 12 months. The 10-Q provides detailed financial statements and disclosures, including a lease termination agreement for 1200 Page Mill Road and a new option for 1100 Page Mill Road, as well as updates on clinical trials with key data readouts expected in September and December 2026.
At the time of this filing, KOD was trading at $40.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $8.29 to $47.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.